Expert oncologists Andy Seidman, MD; Vijayakrishna Gadi, MD, PhD; Tiffany Traina, MD; William Gradishar, MD; and Stephanie Graff, MD, review data from ASCO 2022 and share updates in the management of HER2+ and HER2-low breast cancer.
June 27th 2022
Expert oncologists review adjuvant treatment strategies in early stage HER2+ breast cancer and consider when observation alone would be appropriate.
Shared insight on the optimal use of HER2 dual-blockade strategies in patients with early stage HER2+ breast cancer.
July 4th 2022
Panelists review clinical data behind subcutaneous HP therapy in early stage HER2+ breast cancer and elucidate the real-world use of this approach.
A brief discussion on the role of trastuzumab emtansine, T-DM1, in patients with early-stage HER2+ breast cancer.
July 11th 2022
Expert oncologists share their perspectives on when it would be appropriate to consider neratinib therapy in early-stage HER2+ breast cancer.
Subject matter experts in breast oncology discuss ongoing clinical trials in early-stage HER2+ breast cancer that focus on perioperative therapies.
July 18th 2022
Before closing out their discussion on early-stage HER2+ breast cancer, expert oncologists define the value of escalating or deescalating therapy.
Shared insight on the treatment armamentarium for patients diagnosed with HER2+ metastatic breast cancer.
July 25th 2022
Homing in on trastuzumab deruxtecan, T-DXd, expert panelists review recent safety data in the setting of HER2+ metastatic breast cancer.
Focusing on the management of brain metastases in HER2+ metastatic breast cancer, panelists share trial data on tucatinib and trastuzumab deruxtecan.
August 1st 2022
Comprehensive discussion on how oncologists may practically select and sequence novel treatment approaches in HER2+ metastatic breast cancer.
Before sharing a final review of treatment options for HER2+ metastatic breast cancer, expert oncologists highlight ongoing clinical trials in this setting.
August 8th 2022
Expert perspectives on the advent of HER2-low disease and how it has been historically managed since its emergence as a subset of breast cancer.
Comprehensive insight on the novel treatment strategies available for patients diagnosed with HER2-low breast cancer.
August 15th 2022
Panelists focus on clinical trial data driving use of novel agents in the setting of HER2-low breast cancer and consider how they might select specific therapies.
Before closing out their panel on HER2+ breast cancer, expert oncologists share closing thoughts and their excitement for the evolving treatment landscape.